

Charlie Strange

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/6276256/charlie-strange-publications-by-year.pdf>

Version: 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

185
papers

10,443
citations

48
h-index

100
g-index

213
ext. papers

12,319
ext. citations

5.5
avg, IF

5.78
L-index

#	Paper	IF	Citations
185	PRIMUS - Prompt Initiation of Maintenance Therapy in the US: A Real-World Analysis of Clinical and Economic Outcomes Among Patients Initiating Triple Therapy Following a COPD Exacerbation.. <i>International Journal of COPD</i> , 2022 , 17, 329-342	3	2
184	Feasibility of RESP-FIT: Technology-Enhanced Self-Management Intervention for Adults with COPD. <i>International Journal of COPD</i> , 2021 , 16, 3263-3273	3	0
183	Community-acquired Pneumonia Guideline Recommendations-Impact of a Consensus-based Process versus Systematic Reviews. <i>Clinical Infectious Diseases</i> , 2021 , 73, e1467-e1475	11.6	0
182	A population-based estimate of the health care burden of obstructive sleep apnea using a STOP-BAG questionnaire in South Carolina. <i>Journal of Clinical Sleep Medicine</i> , 2021 , 17, 367-374	3.1	5
181	Relationship between alpha-1 antitrypsin deficiency and obstructive sleep apnea. <i>Sleep and Breathing</i> , 2021 , 25, 2091-2097	3.1	1
180	Overexpression of alpha-1 antitrypsin in mesenchymal stromal cells improves their intrinsic biological properties and therapeutic effects in nonobese diabetic mice. <i>Stem Cells Translational Medicine</i> , 2021 , 10, 320-331	6.9	5
179	Alpha-1 antitrypsin suppresses macrophage activation and promotes islet graft survival after intrahepatic islet transplantation. <i>American Journal of Transplantation</i> , 2021 , 21, 1713-1724	8.7	3
178	Gene coexpression networks reveal novel molecular endotypes in alpha-1 antitrypsin deficiency. <i>Thorax</i> , 2021 , 76, 134-143	7.3	3
177	Updates in the Management of Alpha-1 Antitrypsin Deficiency Lung Disease. <i>US Respiratory & Pulmonary Diseases</i> , 2021 , 6, 26	0.1	0
176	Proteomic Analysis of Exosomes Secreted from Human Alpha-1 Antitrypsin Overexpressing Mesenchymal Stromal Cells.. <i>Biology</i> , 2021 , 11,	4.9	1
175	Alpha-1 Antitrypsin Augmentation Therapy Improves Survival in Severely Deficient Patients with Predicted FEV1 Between 10% and 60%: A Retrospective Analysis of the NHLBI Alpha-1 Antitrypsin Deficiency Registry. <i>International Journal of COPD</i> , 2020 , 15, 3193-3199	3	3
174	Endobronchial coils for emphysema: Dual mechanism of action on lobar residual volume reduction. <i>Respirology</i> , 2020 , 25, 1160-1166	3.6	8
173	Updated guidance on the management of COVID-19: from an American Thoracic Society/European Respiratory Society coordinated International Task Force (29 July 2020). <i>European Respiratory Review</i> , 2020 , 29,	9.8	50
172	Alpha-1 Antitrypsin Deficiency Associated COPD. <i>Clinics in Chest Medicine</i> , 2020 , 41, 339-345	5.3	6
171	Comorbidity Associations with AATD Among Commercially Insured and Medicare Beneficiaries with COPD in the US. <i>International Journal of COPD</i> , 2020 , 15, 2389-2397	3	2
170	Improving the Lives of Patients with Alpha-1 Antitrypsin Deficiency. <i>International Journal of COPD</i> , 2020 , 15, 3313-3322	3	3
169	Prevalence of self-reported sleep problems amongst adults with obstructive airway disease in the NHANES cohort in the United States. <i>Sleep and Breathing</i> , 2020 , 24, 985-993	3.1	6

168	Detection of alpha-1 antitrypsin deficiency: the past, present and future. <i>Orphanet Journal of Rare Diseases</i> , 2020 , 15, 96	4.2	7
167	Effect of Zephyr Endobronchial Valves on Dyspnea, Activity Levels, and Quality of Life at One Year. Results from a Randomized Clinical Trial. <i>Annals of the American Thoracic Society</i> , 2020 , 17, 829-838	4.7	9
166	Progression of Interstitial Lung Disease in Systemic Sclerosis: The Importance of Pneumoproteins Krebs von den Lungen 6 and CCL18. <i>Arthritis and Rheumatology</i> , 2019 , 71, 2059-2067	9.5	29
165	Evaluating fluticasone furoate + vilanterol for the treatment of chronic obstructive pulmonary disease (COPD). <i>Expert Opinion on Pharmacotherapy</i> , 2019 , 20, 1075-1085	4	2
164	Predictors of Response to Endobronchial Coil Therapy in Patients With Advanced Emphysema. <i>Chest</i> , 2019 , 155, 928-937	5.3	20
163	Analysis of the MILES cohort reveals determinants of disease progression and treatment response in lymphangioleiomyomatosis. <i>European Respiratory Journal</i> , 2019 , 53,	13.6	18
162	Proteomic biomarkers of cognitive impairment in obstructive sleep apnea syndrome. <i>Sleep and Breathing</i> , 2019 , 23, 251-257	3.1	8
161	Anxiety and depression in patients with alpha-1 antitrypsin deficiency: current insights and impact on quality of life. <i>Therapeutics and Clinical Risk Management</i> , 2019 , 15, 959-964	2.9	7
160	Clathrin-mediated Endocytosis of Alpha-1 Antitrypsin is Essential for its Protective Function in Islet Cell Survival. <i>Theranostics</i> , 2019 , 9, 3940-3951	12.1	12
159	Patient-reported outcomes of dual bronchodilator fixed-dose combination versus bronchodilator monotherapy in individuals with COPD. <i>International Journal of COPD</i> , 2019 , 14, 1377-1388	3	4
158	Evidence-Based Medicine and the American Thoracic Society Guidelines. <i>JAMA Internal Medicine</i> , 2019 , 179, 1003-1004	11.5	0
157	A Retrospective Claims Analysis of Dual Bronchodilator Fixed-Dose Combination Versus Bronchodilator Monotherapy in Patients with Chronic Obstructive Pulmonary Disease. <i>Chronic Obstructive Pulmonary Diseases (Miami, Fla)</i> , 2019 , 6, 221-232	2.7	1
156	Clinical And Economic Burden Of Eosinophilic COPD In A Large Retrospective US Cohort. <i>International Journal of COPD</i> , 2019 , 14, 2625-2637	3	2
155	Islet Harvest in Carbon Monoxide-Saturated Medium for Chronic Pancreatitis Patients Undergoing Islet Autotransplantation. <i>Cell Transplantation</i> , 2019 , 28, 255-365	4	8
154	Therapeutic Effects of Adipose Stem Cells from Diabetic Mice for the Treatment of Type 2 Diabetes. <i>Molecular Therapy</i> , 2018 , 26, 1921-1930	11.7	40
153	Mortality in Asthma-Chronic Obstructive Pulmonary Disease Overlap in the United States. <i>Southern Medical Journal</i> , 2018 , 111, 293-298	0.6	6
152	Autologous Mesenchymal Stem Cell and Islet Cotransplantation: Safety and Efficacy. <i>Stem Cells Translational Medicine</i> , 2018 , 7, 11-19	6.9	32
151	Reliability and minimal clinically important differences of forced vital capacity: Results from the Scleroderma Lung Studies (SLS-I and SLS-II). <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018 , 197, 644-652	10.2	47

150	Sequencing Alpha-1 MZ Individuals Shows Frequent Biallelic Mutations. <i>Pulmonary Medicine</i> , 2018 , 2018, 2836389	5.3	6
149	Oropharyngeal swallow physiology and swallowing-related quality of life in underweight patients with concomitant advanced chronic obstructive pulmonary disease. <i>International Journal of COPD</i> , 2018 , 13, 2663-2671	3	22
148	Inhaled corticosteroids for chronic obstructive pulmonary disease: what is their role in therapy?. <i>International Journal of COPD</i> , 2018 , 13, 2587-2601	3	40
147	A Multicenter Randomized Controlled Trial of Zephyr Endobronchial Valve Treatment in Heterogeneous Emphysema (LIBERATE). <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018 , 198, 1151-1164	10.2	138
146	Anti-Proteases and Alpha-1 Antitrypsin Augmentation Therapy. <i>Respiratory Care</i> , 2018 , 63, 690-698	2.1	12
145	E1 Antitrypsin Enhances Islet Engraftment by Suppression of Instant Blood-Mediated Inflammatory Reaction. <i>Diabetes</i> , 2017 , 66, 970-980	0.9	50
144	Use of multitarget tyrosine kinase inhibitors to attenuate platelet-derived growth factor signalling in lung disease. <i>European Respiratory Review</i> , 2017 , 26,	9.8	11
143	Adipose stem cells from chronic pancreatitis patients improve mouse and human islet survival and function. <i>Stem Cell Research and Therapy</i> , 2017 , 8, 192	8.3	15
142	Adipose Stem Cell Therapy Mitigates Chronic Pancreatitis via Differentiation into Acinar-like Cells in Mice. <i>Molecular Therapy</i> , 2017 , 25, 2490-2501	11.7	13
141	Lymphangioliomyomatosis Diagnosis and Management: High-Resolution Chest Computed Tomography, Transbronchial Lung Biopsy, and Pleural Disease Management. An Official American Thoracic Society/Japanese Respiratory Society Clinical Practice Guideline. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017 , 196, 1337-1348	10.2	97
140	COPD in individuals with the PiMZ alpha-1 antitrypsin genotype. <i>European Respiratory Review</i> , 2017 , 26,	9.8	10
139	A review of current and developing fixed-dose LABA/LAMA combinations for treating COPD. <i>Expert Opinion on Pharmacotherapy</i> , 2017 , 18, 1833-1843	4	3
138	Serum Proteins Associated with Emphysema Progression in Severe Alpha-1 Antitrypsin Deficiency. <i>Chronic Obstructive Pulmonary Diseases (Miami, Fla)</i> , 2017 , 4, 204-216	2.7	3
137	Establishing the USA Registry: Logistics, Impact, and Early Clinical Trials 2017 , 207-211		
136	Spotlight on fluticasone furoate/umeclidinium/vilanterol in COPD: design, development, and potential place in therapy. <i>International Journal of COPD</i> , 2017 , 12, 135-140	3	2
135	Official American Thoracic Society/Japanese Respiratory Society Clinical Practice Guidelines: Lymphangioliomyomatosis Diagnosis and Management. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2016 , 194, 748-61	10.2	160
134	Reply: Asthma/COPD Overlap Syndrome and Medicare 30-Day Readmissions. <i>Annals of the American Thoracic Society</i> , 2016 , 13, 1192	4.7	1
133	Gender and asthma-chronic obstructive pulmonary disease overlap syndrome. <i>Journal of Asthma</i> , 2016 , 53, 720-31	1.9	25

132	Respiratory and lower limb muscle function in interstitial lung disease. <i>Chronic Respiratory Disease</i> , 2016 , 13, 162-72	3	33
131	Rapid oral desensitization to sirolimus in a patient with lymphangioleiomyomatosis. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2016 , 4, 352-3	5.4	5
130	Impact of obstructive sleep apnea syndrome on cognition in early postmenopausal women. <i>Sleep and Breathing</i> , 2016 , 20, 621-6	3.1	9
129	Characteristics and Prevalence of Asthma/Chronic Obstructive Pulmonary Disease Overlap in the United States. <i>Annals of the American Thoracic Society</i> , 2016 , 13, 803-10	4.7	68
128	A Novel Quantitative Computed Tomographic Analysis Suggests How Sirolimus Stabilizes Progressive Air Trapping in Lymphangioleiomyomatosis. <i>Annals of the American Thoracic Society</i> , 2016 , 13, 342-9	4.7	18
127	Characteristics of COPD Patients Using United States Emergency Care or Hospitalization. <i>Chronic Obstructive Pulmonary Diseases (Miami, Fla)</i> , 2016 , 3, 539-548	2.7	14
126	Health Care Utilization and Costs After Initiating Budesonide/Formoterol Combination or Fluticasone/Salmeterol Combination Among COPD Patients New to ICS/LABA Treatment. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2016 , 22, 293-304	1.9	6
125	The Diagnosis and Management of Alpha-1 Antitrypsin Deficiency in the Adult. <i>Chronic Obstructive Pulmonary Diseases (Miami, Fla)</i> , 2016 , 3, 668-682	2.7	102
124	Effect of Endobronchial Coils vs Usual Care on Exercise Tolerance in Patients With Severe Emphysema: The RENEW Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , 2016 , 315, 2178-89	27.4	160
123	Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial. <i>Lancet Respiratory Medicine</i> , 2016 , 4, 708-719	35.1	487
122	Segmental approach to lung volume reduction therapy for emphysema patients. <i>Respiration</i> , 2015 , 89, 76-81	3.7	17
121	Acclidinium bromide plus formoterol for the treatment of chronic obstructive pulmonary disease. <i>Expert Opinion on Pharmacotherapy</i> , 2015 , 16, 427-34	4	2
120	The social environment and illness uncertainty in chronic obstructive pulmonary disease. <i>International Journal of Behavioral Medicine</i> , 2015 , 22, 223-32	2.6	14
119	The United States Alpha-1 Foundation Research Registry: Genesis, Impact and Future. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2015 , 12 Suppl 1, 42-5	2	10
118	Comparative effectiveness of budesonide/formoterol combination and fluticasone/salmeterol combination among chronic obstructive pulmonary disease patients new to controller treatment: a US administrative claims database study. <i>Respiratory Research</i> , 2015 , 16, 52	7.3	24
117	Treatment of Alpha-1 Antitrypsin Deficiency. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2015 , 36, 470-7	3.9	7
116	Rationale and Design of the Genomic Research in Alpha-1 Antitrypsin Deficiency and Sarcoidosis Study. Alpha-1 Protocol. <i>Annals of the American Thoracic Society</i> , 2015 , 12, 1551-60	4.7	6
115	Cyst-based measurements for assessing lymphangioleiomyomatosis in computed tomography. <i>Medical Physics</i> , 2015 , 42, 2287-95	4.4	4

114	Patterns of Emphysema Heterogeneity. <i>Respiration</i> , 2015 , 90, 402-11	3.7	26
113	Comparative effectiveness of budesonide/formoterol combination and tiotropium bromide among COPD patients new to these controller treatments. <i>International Journal of COPD</i> , 2015 , 10, 2055-66	3	9
112	Validation of an administrative claims-based diagnostic code for pneumonia in a US-based commercially insured COPD population. <i>International Journal of COPD</i> , 2015 , 10, 1417-25	3	14
111	Smoking duration, respiratory symptoms, and COPD in adults aged ≥5 years with a smoking history. <i>International Journal of COPD</i> , 2015 , 10, 1409-16	3	68
110	Body mass index, respiratory conditions, asthma, and chronic obstructive pulmonary disease. <i>Respiratory Medicine</i> , 2015 , 109, 851-9	4.6	33
109	Impact of medications on cognitive function in obstructive sleep apnea syndrome. <i>Sleep and Breathing</i> , 2015 , 19, 939-45	3.1	5
108	Clinical Trial Design for Alpha-1 Antitrypsin Deficiency: A Model for Rare Diseases. <i>Chronic Obstructive Pulmonary Diseases (Miami, Fla)</i> , 2015 , 2, 177-190	2.7	6
107	Targeting Persons With or At High Risk for Chronic Obstructive Pulmonary Disease by State-based Surveillance. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2015 , 12, 680-9	2	4
106	Multiorgan system dysfunction in the chylomicronemia syndrome. <i>Journal of Intensive Care Medicine</i> , 2014 , 29, 175-8	3.3	3
105	Expanded carrier screening panels-does bigger mean better?. <i>Journal of Community Genetics</i> , 2014 , 5, 191-8	2.5	34
104	Detection of alpha-1 antitrypsin deficiency by respiratory therapists: experience with an educational program. <i>Respiratory Care</i> , 2014 , 59, 667-72	2.1	9
103	Effect of obstructive sleep apnea treatment on mail-in cognitive function screening instrument. <i>American Journal of the Medical Sciences</i> , 2014 , 348, 215-8	2.2	7
102	Circulating polymers in α1-antitrypsin deficiency. <i>European Respiratory Journal</i> , 2014 , 43, 1501-4	13.6	50
101	The impact of age on outcomes in chronic obstructive pulmonary disease differs by relationship status. <i>Journal of Behavioral Medicine</i> , 2014 , 37, 654-63	3.6	21
100	The prospective association of perceived criticism with dyspnea in chronic lung disease. <i>Journal of Psychosomatic Research</i> , 2013 , 74, 450-3	4.1	1
99	Genetics influence on patient experiences with a rare chronic disorder: a photovoice study of living with alpha-1 antitrypsin deficiency. <i>Nursing Clinics of North America</i> , 2013 , 48, 627-36	1.6	3
98	Serum VEGF-D a concentration as a biomarker of lymphangioliomyomatosis severity and treatment response: a prospective analysis of the Multicenter International Lymphangioliomyomatosis Efficacy of Sirolimus (MILES) trial. <i>Lancet Respiratory Medicine</i> , 2013 , 1, 445-52	35.1	119
97	Airway disease in alpha-1 antitrypsin deficiency. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2013 , 10 Suppl 1, 68-73	2	16

96	Safety and pharmacokinetics of 120 mg/kg versus 60 mg/kg weekly intravenous infusions of alpha-1 proteinase inhibitor in alpha-1 antitrypsin deficiency: a multicenter, randomized, double-blind, crossover study (SPARK). <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2013 , 10, 687-95	2	45
95	Differences in adjustment between individuals with alpha-1 antitrypsin deficiency (AATD)-associated COPD and non-AATD COPD. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2013 , 10, 226-34	2	12
94	Inhaled alpha 1-antitrypsin: gauging patient interest in a new treatment. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2013 , 10, 411-5	2	20
93	S64 Circulating polymers are found in alpha-1-antitrypsin deficiency and are associated with lung disease. <i>Thorax</i> , 2013 , 68, A35.1-A35	7.3	
92	Baseline regional perfusion impacts exercise response to endobronchial valve therapy in advanced pulmonary emphysema. <i>Chest</i> , 2013 , 144, 1578-1586	5.3	28
91	Prospective impact of illness uncertainty on outcomes in chronic lung disease. <i>Health Psychology</i> , 2013 , 32, 1170-4	5	21
90	Association of IREB2 and CHRNA3 polymorphisms with airflow obstruction in severe alpha-1 antitrypsin deficiency. <i>Respiratory Research</i> , 2012 , 13, 16	7.3	39
89	Association of cigarette smoking and CRP levels with DNA methylation in α 1 antitrypsin deficiency. <i>Epigenetics</i> , 2012 , 7, 720-8	5.7	19
88	An official American Thoracic Society clinical practice guideline: the clinical utility of bronchoalveolar lavage cellular analysis in interstitial lung disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2012 , 185, 1004-14	10.2	593
87	Perspectives for improving the evaluation and access of therapies for rare lung diseases in Europe. <i>Respiratory Medicine</i> , 2012 , 106, 759-68	4.6	20
86	Monitoring of nonsteroidal immunosuppressive drugs in patients with lung disease and lung transplant recipients: American College of Chest Physicians evidence-based clinical practice guidelines. <i>Chest</i> , 2012 , 142, e15-e111S	5.3	37
85	Rude awakening: acute abdominal pain with spontaneous resolution. <i>American Journal of Medicine</i> , 2012 , 125, 971-3	2.4	1
84	Alpha-1 antitrypsin deficiency targeted testing and augmentation therapy: a Canadian Thoracic Society clinical practice guideline. <i>Canadian Respiratory Journal</i> , 2012 , 19, 109-16	2.1	64
83	Emphysema lung lobe volume reduction: effects on the ipsilateral and contralateral lobes. <i>European Radiology</i> , 2012 , 22, 1547-55	8	32
82	Alcohol use predicts ER visits in individuals with alpha-1 antitrypsin deficiency (AATD) associated COPD. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2012 , 9, 417-25	2	3
81	The prevalence of alpha-1 antitrypsin deficiency among patients found to have airflow obstruction. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2012 , 9, 352-8	2	40
80	Executive summary: monitoring of nonsteroidal immunosuppressive drugs in patients with lung disease and lung transplant recipients: American College of Chest Physicians evidence-based clinical practice guidelines. <i>Chest</i> , 2012 , 142, 1284-1288	5.3	6
79	Neurocognitive impairment in obstructive sleep apnea. <i>Chest</i> , 2012 , 141, 1601-1610	5.3	259

78	Efficacy and safety of sirolimus in lymphangi leiomyomatosis. <i>New England Journal of Medicine</i> , 2011 , 364, 1595-606	59.2	724
77	Adverse events during the Scleroderma Lung Study. <i>American Journal of Medicine</i> , 2011 , 124, 459-67	2.4	24
76	The Alpha-1 Association Genetic Counseling Program: an innovative approach to service. <i>Journal of Genetic Counseling</i> , 2011 , 20, 330-6	2.5	5
75	Unilateral pulmonary artery aplasia in a pregnant patient. <i>Case Reports in Medicine</i> , 2011 , 2011, 806723	0.7	2
74	Is PiSS Alpha-1 Antitrypsin Deficiency Associated with Disease?. <i>Pulmonary Medicine</i> , 2010 , 2010, 570679	5.3	11
73	A randomized study of endobronchial valves for advanced emphysema. <i>New England Journal of Medicine</i> , 2010 , 363, 1233-44	59.2	562
72	Pulmonary manifestations of systemic lupus erythematosus. <i>Clinics in Chest Medicine</i> , 2010 , 31, 479-88	5.3	94
71	Pharmacokinetic comparability of Prolastin [®] -C to Prolastin [®] in alpha ¹ -antitrypsin deficiency: a randomized study. <i>BMC Clinical Pharmacology</i> , 2010 , 10, 13		28
70	Alpha-1 Antitrypsin Deficiency 2010 , 209-224		1
69	Development of predictive models for airflow obstruction in alpha-1-antitrypsin deficiency. <i>American Journal of Epidemiology</i> , 2009 , 170, 1005-13	3.8	22
68	Heritability of lung function in severe alpha-1 antitrypsin deficiency. <i>Human Heredity</i> , 2009 , 67, 38-45	1.1	22
67	Biologic lung volume reduction in advanced upper lobe emphysema: phase 2 results. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2009 , 179, 791-8	10.2	89
66	Limitations to the 6-minute walk test in interstitial lung disease and pulmonary hypertension in scleroderma. <i>Journal of Rheumatology</i> , 2009 , 36, 330-6	4.1	96
65	Connective Tissue Disease and Vasculitis-Associated Interstitial Lung Disease 2009 , 159-175		0
64	IL10 polymorphisms are associated with airflow obstruction in severe alpha1-antitrypsin deficiency. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2008 , 38, 114-20	5.7	63
63	alpha1-Antitrypsin augmentation therapy for PI*MZ heterozygotes: a cautionary note. <i>Chest</i> , 2008 , 134, 831-834	5.3	43
62	Bronchoalveolar lavage and response to cyclophosphamide in scleroderma interstitial lung disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2008 , 177, 91-8	10.2	120
61	Barriers to genetic testing among persons at risk for alpha-1 antitrypsin deficiency. <i>Genetic Testing and Molecular Biomarkers</i> , 2008 , 12, 501-5		5

60	A 56-year-old woman with arm pain, dyspnea, and an elevated diaphragm. <i>Chest</i> , 2008 , 133, 296-9	5.3	12
59	Prognostic Significance of Bronchoalveolar Lavage Cellular Analysis in Scleroderma Lung Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2008 , 177, 1293-1293	10.2	0
58	Sitaxsentan for the treatment of pulmonary arterial hypertension: a 1-year, prospective, open-label observation of outcome and survival. <i>Chest</i> , 2008 , 134, 775-782	5.3	82
57	Massive Hemoptysis 2008 , 929-948		1
56	Radiation therapy for palliation of Eisenmenger's syndrome-associated painful splenomegaly. <i>Radiation Medicine</i> , 2008 , 26, 84-7		3
55	Impact of oral cyclophosphamide on health-related quality of life in patients with active scleroderma lung disease: results from the scleroderma lung study. <i>Arthritis and Rheumatism</i> , 2007 , 56, 1676-84		82
54	Design of the Endobronchial Valve for Emphysema Palliation Trial (VENT): a non-surgical method of lung volume reduction. <i>BMC Pulmonary Medicine</i> , 2007 , 7, 10	3.5	64
53	Infection in the intensive care unit: a clinician's view of the role of imaging. <i>Seminars in Roentgenology</i> , 2007 , 42, 7-10	0.8	1
52	Does genetic testing result in behavioral health change? Changes in smoking behavior following testing for alpha-1 antitrypsin deficiency. <i>Annals of Behavioral Medicine</i> , 2007 , 33, 22-8	4.5	72
51	Determinants of airflow obstruction in severe alpha-1-antitrypsin deficiency. <i>Thorax</i> , 2007 , 62, 806-13	7.3	78
50	Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2007 , 176, 1026-34	10.2	343
49	Hypoglycemia risk: A cause for concern in the intensive care unit hyperglycemia control debate. <i>Critical Care Medicine</i> , 2007 , 35, 1222-e11	1.4	
48	Cyclophosphamide versus placebo in scleroderma lung disease. <i>New England Journal of Medicine</i> , 2006 , 354, 2655-66	59.2	1125
47	Results of a survey of patients with alpha-1 antitrypsin deficiency. <i>Respiration</i> , 2006 , 73, 185-90	3.7	47
46	Multi-center study: the biochemical efficacy, safety and tolerability of a new alpha1-proteinase inhibitor, Zemaira. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2006 , 3, 17-23	2	39
45	Asthma and allergy in alpha-1 antitrypsin deficiency. <i>Respiratory Medicine</i> , 2006 , 100, 1384-91	4.6	37
44	Genetic testing of minors for alpha1-antitrypsin deficiency. <i>JAMA Pediatrics</i> , 2006 , 160, 531-4		18
43	Evaluation of an intensive insulin protocol for septic patients in a medical intensive care unit. <i>Critical Care Medicine</i> , 2006 , 34, 2974-8	1.4	73

42	Factors associated with advanced liver disease in adults with alpha1-antitrypsin deficiency. <i>Clinical Gastroenterology and Hepatology</i> , 2005 , 3, 390-6	6.9	70
41	Treatment for secondary pulmonary hypertension. <i>Chest</i> , 2005 , 128, 1897-8	5.3	7
40	The Rise and Fall of Ultrasound Thoracentesis. <i>Journal of Bronchology</i> , 2005 , 12, 191-192		1
39	Pulmonary hypertension in interstitial lung disease. <i>Current Opinion in Pulmonary Medicine</i> , 2005 , 11, 452-5	3	46
38	Rest in Peace. <i>Journal of Bronchology</i> , 2005 , 12, 131-132		4
37	Delay in diagnosis of alpha1-antitrypsin deficiency: a continuing problem. <i>Chest</i> , 2005 , 128, 1989-94	5.3	159
36	Pneumothorax in cystic fibrosis. <i>Chest</i> , 2005 , 128, 720-8	5.3	85
35	Mortality in individuals with severe deficiency of alpha1-antitrypsin: findings from the National Heart, Lung, and Blood Institute Registry. <i>Chest</i> , 2005 , 127, 1196-204	5.3	58
34	"The lion, the witch and the wardrobe": impact on sibs of individuals with AAT deficiency. <i>American Journal of Medical Genetics Part A</i> , 2004 , 130A, 251-7		4
33	Interstitial lung disease in the patient who has connective tissue disease. <i>Clinics in Chest Medicine</i> , 2004 , 25, 549-59, vii	5.3	98
32	Genetic testing for alpha1-antitrypsin deficiency. <i>Genetics in Medicine</i> , 2004 , 6, 204-10	8.1	35
31	Treatment of pulmonary arterial hypertension: a preliminary decision analysis. <i>Chest</i> , 2003 , 124, 2087-92	5.3	41
30	Long-term effects of inhaled corticosteroids on FEV1 in patients with chronic obstructive pulmonary disease. A meta-analysis. <i>Annals of Internal Medicine</i> , 2003 , 138, 969-73	8	77
29	Hepatopulmonary syndrome occurring after orthotopic liver transplantation. <i>Liver Transplantation</i> , 2001 , 7, 1081-4	4.5	11
28	Management of spontaneous pneumothorax: an American College of Chest Physicians Delphi consensus statement. <i>Chest</i> , 2001 , 119, 590-602	5.3	83
27	Hemodynamic effects of epoprostenol in patients with systemic sclerosis and pulmonary hypertension. <i>Chest</i> , 2000 , 118, 1077-82	5.3	39
26	Pleural complications in the intensive care unit. <i>Clinics in Chest Medicine</i> , 1999 , 20, 317-27	5.3	28
25	Treatment of spontaneous pneumothorax: a more aggressive approach?. <i>Chest</i> , 1997 , 112, 789-804	5.3	144

24	The clinician's perspective on pneumothorax management. <i>Chest</i> , 1997 , 112, 822-8	5.3	80
23	Cytokine concentrations in bronchoalveolar lavage fluid of patients with systemic sclerosis. <i>Arthritis and Rheumatism</i> , 1997 , 40, 743-51		107
22	Platelets attenuate oxidant-induced permeability in endothelial monolayers: glutathione-dependent mechanisms. <i>Journal of Applied Physiology</i> , 1996 , 81, 1701-6	3.7	7
21	Pleural macrophages differentially alter pleural mesothelial cell glycosaminoglycan production. <i>Experimental Lung Research</i> , 1996 , 22, 101-11	2.3	11
20	Effects of intrapleural heparin or urokinase on the extent of tetracycline-induced pleural disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 1995 , 151, 508-15	10.2	49
19	Talc slurry pleurodesis. Pleural fluid and histologic analysis. <i>Chest</i> , 1995 , 107, 1707-12	5.3	98
18	Empyema thoracis. Therapeutic management and outcome. <i>Chest</i> , 1995 , 107, 1532-7	5.3	105
17	Refractory hypotension during warfarin therapy. <i>Hospital Practice (1995)</i> , 1994 , 29, 121, 124	2.2	
16	Failure of the circulatory system limits exercise performance in patients with systemic sclerosis. <i>American Journal of Medicine</i> , 1993 , 95, 413-8	2.4	29
15	Electron microscopic analysis of the normal and the activated pleural macrophage. <i>Experimental Lung Research</i> , 1993 , 19, 731-42	2.3	8
14	Intrapleural streptokinase in experimental empyema. <i>The American Review of Respiratory Disease</i> , 1993 , 147, 962-6		60
13	A comparison of rotation and nonrotation in tetracycline pleurodesis. <i>Chest</i> , 1993 , 104, 1763-6	5.3	56
12	The clinician's perspective on parapneumonic effusions and empyema. <i>Chest</i> , 1993 , 103, 259-61	5.3	40
11	Early inflammatory response of minocycline and tetracycline on the rabbit pleura. <i>Chest</i> , 1993 , 104, 1585-8	5.3	33
10	Pleural macrophages differentially alter mesothelial cell growth and collagen production. <i>Inflammation</i> , 1993 , 17, 1-12	5.1	18
9	Cyclophosphamide and low-dose prednisone therapy in patients with systemic sclerosis (scleroderma) with interstitial lung disease. <i>Journal of Rheumatology</i> , 1993 , 20, 838-44	4.1	125
8	Chylous transport of amiodarone. <i>Chest</i> , 1992 , 101, 573-4	5.3	8
7	Growth and characterization of fibroblasts obtained from bronchoalveolar lavage of patients with scleroderma. <i>Journal of Rheumatology</i> , 1992 , 19, 1716-23	4.1	45

6	Double-lumen endotracheal tubes. <i>Clinics in Chest Medicine</i> , 1991 , 12, 497-506	5.3	14
5	Management of parapneumonic pleural effusions and empyema. <i>Infectious Disease Clinics of North America</i> , 1991 , 5, 539-59	6.5	5
4	Double-lumen Endotracheal Tubes. <i>Clinics in Chest Medicine</i> , 1991 , 12, 497-506	5.3	16
3	Management of Parapneumonic Pleural Effusions and Empyema. <i>Infectious Disease Clinics of North America</i> , 1991 , 5, 539-559	6.5	20
2	Subglottic stenosis in Wegener's granulomatosis: development during cyclophosphamide treatment with response to carbon dioxide laser therapy. <i>Thorax</i> , 1990 , 45, 300-1	7.3	29
1	The histology of experimental pleural injury with tetracycline, empyema, and carrageenan. <i>Experimental and Molecular Pathology</i> , 1989 , 51, 205-19	4.4	58